PRA International has completed its merger with ReSearch Pharmaceutical Services (“RPS”), following the acquisition of both organisations by KKR. The combination of PRA and RPS creates the fourth largest CRO, offering an enhanced array of services and capabilities to support its clients.
Going forward, RPS will operate as PRA’s Strategic Solutions Division and the combined enterprise will be led by PRA’s CEO Colin Shannon. Former RPS CEO Harris Koffer and President Samir Shah have been named President and COO of the Strategic Solutions Division, respectively.
Colin Shannon, President and CEO of PRA said, “As we join forces with the team at RPS, this begins a new chapter for both organizations. We have a supportive long-term partner in KKR and the combination with RPS makes PRA a stronger organization, offering our customers a more comprehensive range of services through our expanded capabilities and therapeutic expertise. As a division of PRA, the RPS Strategic Solutions Division will continue to operate as RPS has previously, which should enable a seamless integration with absolutely no disruption for our clients.”
Since 2000, PRA has performed approximately 2,000 clinical trials in over 80 countries on behalf of over 300 clients. RPS is known throughout the industry as the pioneer of the Embedded clinical development model and has more than 4,000 employees located in over 64 countries.